188 related articles for article (PubMed ID: 31741234)
21. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
22. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics.
Perry A; Fuller CE; Banerjee R; Brat DJ; Scheithauer BW
Front Biosci; 2003 Jan; 8():a1-9. PubMed ID: 12456321
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.
Choi KY; Jung TY; Jung S; Kim YH; Moon KS; Kim IY; Kang SS; Lee KH
J Neurooncol; 2011 May; 103(1):103-10. PubMed ID: 20737192
[TBL] [Abstract][Full Text] [Related]
24. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
McNamara MG; Jiang H; Lim-Fat MJ; Sahebjam S; Kiehl TR; Karamchandani J; Coire C; Chung C; Millar BA; Laperriere N; Mason WP
Can J Neurol Sci; 2017 May; 44(3):288-294. PubMed ID: 28488951
[TBL] [Abstract][Full Text] [Related]
25. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.
Figarella-Branger D; Mokhtari K; Dehais C; Jouvet A; Uro-Coste E; Colin C; Carpentier C; Forest F; Maurage CA; Vignaud JM; Polivka M; Lechapt-Zalcman E; Eimer S; Viennet G; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Loussouarn D; Lacroix C; Rigau V; Laquerrière A; Vandenbos F; Michalak S; Sevestre H; Peoch M; Labrousse F; Christov C; Kemeny JL; Chenard MP; Chiforeanu D; Ducray F; Idbaih A;
Neuro Oncol; 2014 Sep; 16(9):1244-54. PubMed ID: 24723566
[TBL] [Abstract][Full Text] [Related]
26. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.
Polivka J; Polivka J; Repik T; Rohan V; Hes O; Topolcan O
Anticancer Res; 2016 Jan; 36(1):471-6. PubMed ID: 26722084
[TBL] [Abstract][Full Text] [Related]
27. Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas.
Harary M; Kavouridis VK; Torre M; Zaidi HA; Chukwueke UN; Reardon DA; Smith TR; Iorgulescu JB
Neuro Oncol; 2020 Mar; 22(3):369-380. PubMed ID: 31538193
[TBL] [Abstract][Full Text] [Related]
28. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.
Minniti G; Arcella A; Scaringi C; Lanzetta G; Di Stefano D; Scarpino S; Pace A; Giangaspero F; Osti MF; Enrici RM
J Neurooncol; 2014 Jan; 116(2):275-82. PubMed ID: 24162810
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
van den Bent MJ; Brandes AA; Taphoorn MJ; Kros JM; Kouwenhoven MC; Delattre JY; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Enting RH; French PJ; Dinjens WN; Vecht CJ; Allgeier A; Lacombe D; Gorlia T; Hoang-Xuan K
J Clin Oncol; 2013 Jan; 31(3):344-50. PubMed ID: 23071237
[TBL] [Abstract][Full Text] [Related]
30. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Franceschi E; Tosoni A; De Biase D; Lamberti G; Danieli D; Pizzolitto S; Zunarelli E; Visani M; Di Oto E; Mura A; Minichillo S; Scafati C; Asioli S; Paccapelo A; Bartolini S; Brandes AA
Oncologist; 2019 May; 24(5):664-670. PubMed ID: 30777895
[TBL] [Abstract][Full Text] [Related]
31. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
[TBL] [Abstract][Full Text] [Related]
32. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.
Johnson DR; Diehn FE; Giannini C; Jenkins RB; Jenkins SM; Parney IF; Kaufmann TJ
AJNR Am J Neuroradiol; 2017 Apr; 38(4):678-684. PubMed ID: 28126746
[TBL] [Abstract][Full Text] [Related]
33. Alpha internexin expression related with molecular characteristics in adult glioblastoma and oligodendroglioma.
Suh JH; Park CK; Park SH
J Korean Med Sci; 2013 Apr; 28(4):593-601. PubMed ID: 23579442
[TBL] [Abstract][Full Text] [Related]
34. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
[TBL] [Abstract][Full Text] [Related]
35. Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases.
Shin DW; Lee S; Song SW; Cho YH; Hong SH; Kim JH; Kim HS; Park JE; Nam SJ; Kim YH
Sci Rep; 2020 Nov; 10(1):20162. PubMed ID: 33214617
[TBL] [Abstract][Full Text] [Related]
36. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
37. Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.
Ren X; Jiang H; Cui X; Cui Y; Ma J; Jiang Z; Sui D; Lin S
Neuro Oncol; 2013 Sep; 15(9):1244-50. PubMed ID: 23861470
[TBL] [Abstract][Full Text] [Related]
38. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
[TBL] [Abstract][Full Text] [Related]
39. Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma.
Khan KA; Abbasi AN; Ali N
J Coll Physicians Surg Pak; 2014 Dec; 24(12):935-9. PubMed ID: 25523732
[TBL] [Abstract][Full Text] [Related]
40. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]